Laura Ann Williams Goff, M.D.

Associate Professor
Faculty Appointments
Associate Professor of Medicine
M.S.C.I., Clinical Investigation , Vanderbilt University, Nashville, TennesseeM.D., University of Texas, San Antonio, TexasB.S., Duke University, Durham, North Carolina
Office Address
777 PRB
2220 Pierce Ave
Nashville, TN 37232-6307
Chan E, Goff LW, Cardin DB, Ancell K, Smith SJ, Whisenant JG, Ye F, Berlin JD. Phase II study of the Multikinase inhibitor of angiogenesis, Linifanib, in patients with metastatic and refractory colorectal cancer expressing mutated KRAS. Invest New Drugs [print-electronic]. 2017 Aug; 35(4): 491-8. PMID: 28353122, PII: 10.1007/s10637-017-0458-8, DOI: 10.1007/s10637-017-0458-8, ISSN: 1573-0646.

Cardin DB, Thota R, Goff LW, Berlin JD, Jones CM, Ayers GD, Whisenant JG, Chan E. A Phase II Study of Ganetespib as Second-line or Third-line Therapy for Metastatic Pancreatic Cancer. Am. J. Clin. Oncol [print-electronic]. 2017 Mar 3/15/2017; PMID: 28301350, DOI: 10.1097/COC.0000000000000377, ISSN: 1537-453X.

Goff LW, Cardin DB, Whisenant JG, Du L, Koyama T, Dahlman KB, Salaria SN, Young RT, Ciombor KK, Gilbert J, Smith SJ, Chan E, Berlin J. A phase I trial investigating pulsatile erlotinib in combination with gemcitabine and oxaliplatin in advanced biliary tract cancers. Invest New Drugs [print-electronic]. 2017 Feb; 35(1): 95-104. PMID: 27853997, PMCID: PMC5306261, PII: 10.1007/s10637-016-0406-z, DOI: 10.1007/s10637-016-0406-z, ISSN: 1573-0646.

Pauff JM, Goff LW. Current Progress in Immunotherapy for the Treatment of Biliary Cancers. J Gastrointest Cancer. 2016 Dec; 47(4): 351-7. PMID: 27538880, PII: 10.1007/s12029-016-9867-8, DOI: 10.1007/s12029-016-9867-8, ISSN: 1941-6636.

Chan E, Arlinghaus LR, Cardin DB, Goff L, Berlin JD, Parikh A, Abramson RG, Yankeelov TE, Hiebert S, Merchant N, Bhaskara S, Chakravarthy AB. Phase I trial of vorinostat added to chemoradiation with capecitabine in pancreatic cancer. Radiother Oncol [print-electronic]. 2016 May; 119(2): 312-8. PMID: 27106554, PMCID: PMC4961249, PII: S0167-8140(16)31047-7, DOI: 10.1016/j.radonc.2016.04.013, ISSN: 1879-0887.

Goff LW, Cohen RB, Berlin JD, de Braud FG, Lyshchik A, Noberasco C, Bertolini F, Carpentieri M, Stampino CG, Abbattista A, Wang E, Borghaei H. A Phase I Study of the Anti-Activin Receptor-Like Kinase 1 (ALK-1) Monoclonal Antibody PF-03446962 in Patients with Advanced Solid Tumors. Clin. Cancer Res [print-electronic]. 2016 May 5/1/2016; 22(9): 2146-54. PMID: 26655846, PII: 1078-0432.CCR-15-1622, DOI: 10.1158/1078-0432.CCR-15-1622, ISSN: 1078-0432.

Katsha A, Belkhiri A, Goff L, El-Rifai W. Aurora kinase A in gastrointestinal cancers: time to target. Mol. Cancer. 2015 May 5/20/2015; 14: 106. PMID: 25987188, PMCID: PMC4436812, PII: 10.1186/s12943-015-0375-4, DOI: 10.1186/s12943-015-0375-4, ISSN: 1476-4598.

Puzanov I, Lindsay CR, Goff L, Sosman J, Gilbert J, Berlin J, Poondru S, Simantov R, Gedrich R, Stephens A, Chan E, Evans TR. A phase I study of continuous oral dosing of OSI-906, a dual inhibitor of insulin-like growth factor-1 and insulin receptors, in patients with advanced solid tumors. Clin. Cancer Res [print-electronic]. 2015 Feb 2/15/2015; 21(4): 701-11. PMID: 25212606, PII: 1078-0432.CCR-14-0303, DOI: 10.1158/1078-0432.CCR-14-0303, ISSN: 1078-0432.

Puzanov I, Sosman J, Santoro A, Saif MW, Goff L, Dy GK, Zucali P, Means-Powell JA, Ma WW, Simonelli M, Martell R, Chai F, Lamar M, Savage RE, Schwartz B, Adjei AA. Phase 1 trial of tivantinib in combination with sorafenib in adult patients with advanced solid tumors. Invest New Drugs [print-electronic]. 2015 Feb; 33(1): 159-68. PMID: 25294187, PMCID: PMC4295023, DOI: 10.1007/s10637-014-0167-5, ISSN: 1573-0646.

Johnson DB, Dahlman KH, Knol J, Gilbert J, Puzanov I, Means-Powell J, Balko JM, Lovly CM, Murphy BA, Goff LW, Abramson VG, Crispens MA, Mayer IA, Berlin JD, Horn L, Keedy VL, Reddy NM, Arteaga CL, Sosman JA, Pao W. Enabling a genetically informed approach to cancer medicine: a retrospective evaluation of the impact of comprehensive tumor profiling using a targeted next-generation sequencing panel. Oncologist [print-electronic]. 2014 Jun; 19(6): 616-22. PMID: 24797823, PMCID: PMC4041676, PII: theoncologist.2014-0011, DOI: 10.1634/theoncologist.2014-0011, ISSN: 1549-490X.

Cardin DB, Goff L, Li CI, Shyr Y, Winkler C, DeVore R, Schlabach L, Holloway M, McClanahan P, Meyer K, Grigorieva J, Berlin J, Chan E. Phase II trial of sorafenib and erlotinib in advanced pancreatic cancer. Cancer Med [print-electronic]. 2014 Jun; 3(3): 572-9. PMID: 24574334, PMCID: PMC4101748, DOI: 10.1002/cam4.208, ISSN: 2045-7634.

Shaikh F, Goff LW. Decoding hepatocellular carcinoma: the promise of microRNAs. Hepatobiliary Surg Nutr. 2014 Apr; 3(2): 93-4. PMID: 24812602, PMCID: PMC3999426, PII: hbsn-03-02-093, DOI: 10.3978/j.issn.2304-3881.2014.02.08, ISSN: 2304-3881.

Goff LW, Thakkar N, Du L, Chan E, Tan BR, Cardin DB, McLeod HL, Berlin JD, Zehnbauer B, Fournier C, Picus J, Wang-Gillam A, Lee W, Lockhart AC. Thymidylate synthase genotype-directed chemotherapy for patients with gastric and gastroesophageal junction cancers. PLoS ONE. 2014; 9(9): e107424. PMID: 25232828, PMCID: PMC4169411, PII: PONE-D-14-22736, DOI: 10.1371/journal.pone.0107424, ISSN: 1932-6203.

Ciombor KK, Goff LW. Current therapy and future directions in biliary tract malignancies. Curr Treat Options Oncol. 2013 Sep; 14(3): 337-49. PMID: 23686724, PMCID: PMC3769474, DOI: 10.1007/s11864-013-0237-5, ISSN: 1534-6277.

Infante JR, Bendell JC, Goff LW, Jones SF, Chan E, Sudo T, Burris HA, Berlin JD. Safety, pharmacokinetics and pharmacodynamics of the anti-A33 fully-human monoclonal antibody, KRN330, in patients with advanced colorectal cancer. Eur. J. Cancer [print-electronic]. 2013 Apr; 49(6): 1169-75. PMID: 23294608, PII: S0959-8049(12)00929-X, DOI: 10.1016/j.ejca.2012.11.033, ISSN: 1879-0852.

Venepalli NK, Goff L. Targeting the HGF-cMET Axis in Hepatocellular Carcinoma. Int J Hepatol [print-electronic]. 2013; 2013: 341636. PMID: 23606971, PMCID: PMC3626399, DOI: 10.1155/2013/341636, ISSN: 2090-3448.

Ciombor KK, Goff LW. Advances in the management of biliary tract cancers. Clin Adv Hematol Oncol. 2013 Jan; 11(1): 28-34. PMID: 23416860, PMCID: PMC3713630, ISSN: 1543-0790.

Chi M, Mikhitarian K, Shi C, Goff LW. Management of combined hepatocellular-cholangiocarcinoma: a case report and literature review. Gastrointest Cancer Res. 2012 Nov; 5(6): 199-202. PMID: 23293701, PMCID: PMC3533848, ISSN: 1934-7820.

Goff LW, Benson AB, LoRusso PM, Tan AR, Berlin JD, Denis LJ, Benner RJ, Yin D, Rothenberg ML. Phase I study of oral irinotecan as a single-agent and given sequentially with capecitabine. Invest New Drugs [print-electronic]. 2012 Feb; 30(1): 290-8. PMID: 20857171, DOI: 10.1007/s10637-010-9528-x, ISSN: 1573-0646.

Goff LW, Berlin JD. Advanced biliary tract cancers. Am Soc Clin Oncol Educ Book. 2012; 281-2. PMID: 24451749, PII: 203, DOI: 10.14694/EdBook_AM.2012.32.281, ISSN: 1548-8748.

Bekaii-Saab T, Phelps MA, Li X, Saji M, Goff L, Kauh JS, O'Neil BH, Balsom S, Balint C, Liersemann R, Vasko VV, Bloomston M, Marsh W, Doyle LA, Ellison G, Grever M, Ringel MD, Villalona-Calero MA. Multi-institutional phase II study of selumetinib in patients with metastatic biliary cancers. J. Clin. Oncol [print-electronic]. 2011 Jun 6/10/2011; 29(17): 2357-63. PMID: 21519026, PMCID: PMC3107751, PII: JCO.2010.33.9473, DOI: 10.1200/JCO.2010.33.9473, ISSN: 1527-7755.

O'Neil BH, Goff LW, Kauh JS, Strosberg JR, Bekaii-Saab TS, Lee RM, Kazi A, Moore DT, Learoyd M, Lush RM, Sebti SM, Sullivan DM. Phase II study of the mitogen-activated protein kinase 1/2 inhibitor selumetinib in patients with advanced hepatocellular carcinoma. J. Clin. Oncol [print-electronic]. 2011 Jun 6/10/2011; 29(17): 2350-6. PMID: 21519015, PMCID: PMC3107750, PII: JCO.2010.33.9432, DOI: 10.1200/JCO.2010.33.9432, ISSN: 1527-7755.

Mukherjee K, Chakravarthy AB, Goff LW, El-Rifai W. Esophageal adenocarcinoma: treatment modalities in the era of targeted therapy. Dig. Dis. Sci [print-electronic]. 2010 Dec; 55(12): 3304-14. PMID: 20300841, PMCID: PMC2890301, DOI: 10.1007/s10620-010-1187-4, ISSN: 1573-2568.

Ewing GP, Goff LW. The insulin-like growth factor signaling pathway as a target for treatment of colorectal carcinoma. Clin Colorectal Cancer. 2010 Oct; 9(4): 219-23. PMID: 20920993, PII: S1533-0028(11)70005-6, DOI: 10.3816/CCC.2010.n.032, ISSN: 1938-0674.

Dar AA, Goff LW, Majid S, Berlin J, El-Rifai W. Aurora kinase inhibitors--rising stars in cancer therapeutics?. Mol. Cancer Ther [print-electronic]. 2010 Feb; 9(2): 268-78. PMID: 20124450, PMCID: PMC2820587, PII: 1535-7163.MCT-09-0765, DOI: 10.1158/1535-7163.MCT-09-0765, ISSN: 1538-8514.

Pohlmann PR, Mernaugh RL, Goff LW. Chemotherapy and immunotherapy in metastatic colorectal cancer [letter]. N. Engl. J. Med. 2009 May 5/14/2009; 360(20): 2134; author reply 2135-6. PMID: 19439750, PII: 360/20/2134, DOI: 10.1056/NEJMc090489, ISSN: 1533-4406.

Benson AB, Abrams TA, Ben-Josef E, Bloomston PM, Botha JF, Clary BM, Covey A, Curley SA, D'Angelica MI, Davila R, Ensminger WD, Gibbs JF, Laheru D, Malafa MP, Marrero J, Meranze SG, Mulvihill SJ, Park JO, Posey JA, Sachdev J, Salem R, Sigurdson ER, Sofocleous C, Vauthey JN, Venook AP, Goff LW, Yen Y, Zhu AX. NCCN clinical practice guidelines in oncology: hepatobiliary cancers. J Natl Compr Canc Netw. 2009 Apr; 7(4): 350-91. PMID: 19406039, PMCID: PMC4461147.

Goff LW, Rothenberg ML, Lockhart AC, Roth BJ, VerMeulen WL, Chan E, Berlin JD. A phase I trial of irinotecan alternating with epirubicin in patients with advanced malignancies. Am. J. Clin. Oncol. 2008 Oct; 31(5): 413-6. PMID: 18838875, PII: 00000421-200810000-00002, DOI: 10.1097/COC.0b013e318168ef2a, ISSN: 1537-453X.